GlassScriptPhysician profile
Lori Durham Stiegemeier
NPI 1699090159
$973.34
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $420 · 2021: $237 · 2024: $17.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $253.93 | 2019-2021 | |
| Adlon Therapeutics L.P. | $251.54 | 2019-2021 | |
| Tris Pharma INC | $117.66 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.58 | 2019-2021 | |
| Kaleo, INC. | $44.60 | 2020-2021 | |
| Neos Therapeutics, LP | $40.99 | 2020-2021 | |
| Cranial Technologies, INC | $35.02 | 2019-2020 | |
| Sobi, INC | $32.37 | 2020 | |
| Glaxosmithkline, LLC. | $30.52 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $24.02 | 2020-2021 | |
| Sanofi Pasteur INC. | $19.62 | 2021 | |
| Ironshore Pharmaceuticals INC. | $17.38 | 2024 | |
| Alexion Pharmaceuticals, INC. | $12.00 | 2019 | |
| Genentech USA, INC. | $11.13 | 2019 | |
| Phadia US INC. | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Stiegemeier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.